Original Article
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
N Engl J Med 1999; 340:23-30January 7, 1999
- Abstract
Background and Methods
We conducted two multicenter, double-blind, placebo-controlled trials of intermittent administration of inhaled tobramycin in patients with cystic fibrosis and Pseudomonas aeruginosa infection. A total of 520 patients (mean age, 21 years) were randomly assigned to receive either 300 mg of inhaled tobramycin or placebo twice daily for four weeks, followed by four weeks with no study drug. Patients received treatment or placebo in three on–off cycles for a total of 24 weeks. The end points included pulmonary function, the density of P. aeruginosa in sputum, and hospitalization.
Results
The patients treated with inhaled tobramycin had an average increase in forced expiratory volume in one second (FEV1) of 10 percent at week 20 as compared with week 0, whereas the patients receiving placebo had a 2 percent decline in FEV1 (P<0.001). In the tobramycin group, the density of P. aeruginosa decreased by an average of 0.8 log10 colony-forming units (CFU) per gram of expectorated sputum from week 0 to week 20, as compared with an increase of 0.3 log10 CFU per gram in the placebo group (P<0.001). The patients in the tobramycin group were 26 percent (95 percent confidence interval, 2 to 43 percent) less likely to be hospitalized than those in the placebo group. Inhaled tobramycin was not associated with detectable ototoxic or nephrotoxic effects or with accumulation of the drug in serum. The proportion of patients with P. aeruginosa isolates for which the minimal inhibitory concentration of tobramycin was 8 μg per milliliter or higher increased from 25 percent at week 0 to 32 percent at week 24 in the tobramycin group, as compared with a decrease from 20 percent at week 0 to 17 percent at week 24 in the placebo group.
Conclusions
In a 24-week study of patients with cystic fibrosis, intermittent administration of inhaled tobramycin was well tolerated and improved pulmonary function, decreased the density of P. aeruginosa in sputum, and decreased the risk of hospitalization.
Media in This Article
Figure 3
Changes in the Minimal Inhibitory Concentration (MIC) of Tobramycin in P. aeruginosa Isolates from Patients in the Tobramycin Group (Upper Panel) and the Placebo Group (Lower Panel).Figure 2
Mean Change in the Density of P. aeruginosa in Samples of Expectorated Sputum.Article Activity
- Article
Periodic exacerbations of Pseudomonas aeruginosa endobronchial infection in patients with cystic fibrosis have traditionally been treated with parenteral antipseudomonal antibiotics for 7 to 21 days.1 Despite frequent intravenous therapy, patients continue to have a decline in pulmonary function of approximately 2 percent per year, and eventually 90 percent of such patients die of lung disease.2,3 Thus, long-term antibacterial therapy may help maintain pulmonary function.
Other investigators have used inhalation to deliver antibiotics directly to the site of infection.4-7 However, these studies have been limited by small numbers of subjects, short duration, uncertain delivery of antibiotics to the airways, and the absence of a taste-masked placebo. In a multicenter, crossover study, a regimen of 600 mg of inhaled tobramycin delivered with an ultrasonic nebulizer three times a day for up to 56 days was effective and safe, but the regimen was cumbersome and costly.8 A formulation of tobramycin designed for efficient jet nebulization provides similar antibiotic concentrations in airway secretions.9
We report the results of two placebo-controlled, multicenter, randomized, double-blind trials of the efficacy and safety of inhaled tobramycin, delivered by a jet nebulizer, for the treatment of P. aeruginosa infection in patients with cystic fibrosis. We studied whether this regimen would improve pulmonary function, have an antimicrobial effect in sputum, and decrease hospitalizations and the use of intravenous antipseudomonal antibiotics over a period of 24 weeks. In addition, we assessed the safety of this regimen and its effect on the susceptibility of P. aeruginosa to tobramycin.
Methods
Study Design
Two identically designed trials, with a total of 520 patients enrolled at 69 cystic fibrosis centers in the United States, were conducted between August 1995 and October 1996. The base-line characteristics of the patients in the two studies were similar, permitting analyses of pooled data. The eligibility criteria included a documented diagnosis of cystic fibrosis, a respiratory tract culture yielding P. aeruginosa, an age of at least six years, an ability to perform reproducible pulmonary-function tests, and a forced expiratory volume in one second (FEV1) that was at least 25 percent but no more than 75 percent of the predicted value. Criteria for exclusion were receipt of antipseudomonal antibiotics within the previous two weeks, known hypersensitivity to aminoglycosides, compromised renal function (serum creatinine level, ≥2 mg per deciliter [177 mmol per liter]), or recovery of Burkholderia cepacia from the respiratory tract within the previous two years. All patients or their guardians provided written informed consent, and the study was approved by the institutional review board at each participating center.
An adaptive-randomization procedure was used to assign patients in a 1:1 ratio to receive tobramycin or placebo, with stratification according to the ability or inability to produce sputum, the severity of disease as indicated by FEV1 (<50 percent or ≥50 percent), age (6 to 12 years, 13 to 17 years, or ≥18 years), sex, treatment center, presence or absence of concurrent use of dornase alfa (Genentech, South San Francisco, Calif.), and susceptibility of P. aeruginosa to tobramycin (minimal inhibitory concentration [MIC], <8 μg per milliliter or ≥8 μg per milliliter).
Treatment Regimen and Monitoring
The treatment regimen consisted of 300 mg of aerosolized tobramycin or placebo twice daily in three cycles, with each cycle consisting of 28 days during which the drug was administered and 28 days during which it was not administered.
The active drug (tobramycin solution for inhalation, PathoGenesis, Seattle) is a sterile, pH-adjusted solution of 300 mg of preservative-free tobramycin in 5 ml of one-quarter strength normal saline. Taste-masked placebo, chosen to mimic the taste of the active drug, was 1.25 mg of quinine sulfate in 5 ml of one-quarter strength normal saline.8 The study drug was administered with a PARI LC PLUS jet nebulizer (Pari, Richmond, Va.) and a Pulmo-Aide compressor (DeVilbiss, Somerset, Pa.).
During the first cycle, the patients were evaluated every two weeks: at week 0 (the start of the first period of drug administration), week 2, week 4, and week 6. During the second and third cycles, the patients were evaluated every four weeks: at week 8 (the start of the second period of drug administration), week 12, week 16 (the start of the third period of drug administration), week 20 (the end of the third period of drug administration), and week 24 (the follow-up visit). Clinical evaluations and spirometry were performed, and sputum samples (or throat swabs if the patient could not expectorate) were obtained at each visit. At weeks 0, 4, 8, 12, 16, and 20, blood samples were obtained to evaluate drug safety, and auditory acuity was tested. Serum tobramycin levels were determined at weeks 0 and 20. All doses were administered by the patient, who was instructed to wear nose clips and perform normal tidal breathing. Patients were allowed to use their routine medications for the management of cystic fibrosis during the study. However, inhaled antibiotics other than the study drug were prohibited, and patients using dornase alfa or a pneumatic vest (ThAIRapy Vest, American Biosystems, St. Paul, Minn.), or both, were required to begin using them at least four weeks before week 0 and to maintain the same regimen throughout the study.
End Points
The primary end points of the study were lung function (FEV1) and the density of P. aeruginosa in sputum at week 20. Secondary end points included hospitalization and treatment with intravenous antipseudomonal antibiotics.
Pulmonary-function testing was performed in accordance with American Thoracic Society standards.10 Lung function was expressed as the percentage of the value predicted on the basis of norms reported by Knudson et al.,11 and changes were expressed as changes from values at week 0. The relative change in the percentage of the predicted value was calculated as follows:
([Percent predicted at week 20 – percent predicted at week 0]) / percent predicted at week 0) × 100.
Sputum samples were shipped on ice to a central laboratory (at Children's Hospital and Regional Medical Center, Seattle), where quantitative culture and subsequent tobramycin-susceptibility testing of each morphologically distinct P. aeruginosa isolate were performed.12 The MIC of tobramycin for the isolate with the highest MIC cultured from each patient at week 0 and week 24 was documented. The density of P. aeruginosa in sputum was calculated as the log10 value for the sum of all morphotypes (colony-forming units [CFU]) per gram of sputum.
Laboratory studies of safety and drug levels were performed at a central facility. Auditory acuity was tested at 39 centers by certified audiologists. The auditory threshold was determined at frequencies between 250 and 8000 Hz, with the use of a dual-channel audiometer. The criterion for hearing loss was a bilateral decrease of 15 dB or more in the auditory threshold at two consecutive frequencies, as compared with the findings on the first audiogram.
Spirometry was performed before and 30 minutes after administration of the study drug at weeks 0 and 20 to determine the risk of drug-induced bronchospasm. Changes in FEV1 after administration of the study drug are expressed as percentages of the values obtained before administration of the study drug.
Statistical Analysis
Data from all patients who received at least one dose of the study drug were included in the analyses. Between-group comparisons of the mean relative change from week 0 in FEV1 and forced vital capacity and the absolute change in the density of P. aeruginosa in sputum were performed with the use of analysis of variance. The relation between base-line characteristics and changes in FEV1 was assessed with the use of multiple regression. Cox regression models were used to estimate the relative risks of hospitalization and the need for intravenous antipseudomonal antibiotic therapy. The number of days of hospitalization and intravenous antipseudomonal-antibiotic treatment were compared with a Wilcoxon rank-sum test. The number of adverse events was compared with Fisher's exact test. Values were not imputed for missing data.
Results
Of 663 patients screened, 520 met the eligibility criteria and received at least one dose of study drug; 258 patients received tobramycin and 262 received placebo. The treatment groups were similar with respect to randomization strata, lung function, and the density of P. aeruginosa in sputum at week 0 (Table 1Table 1
Base-Line Characteristics of the Patients According to Treatment Assignment.). Two hundred thirty-two of the 258 patients in the tobramycin group (90 percent) and 232 of the 262 patients in the placebo group (89 percent) completed the study. Compliance, as monitored by ampule count, was similar in the two groups, with 88 percent of the patients receiving tobramycin and 93 percent of those receiving placebo using at least 75 percent of the ampules that were dispensed.Lung Function
In the tobramycin group, FEV1, expressed as a percentage of the predicted value, improved during the first two weeks that the patients received the drug and remained above the value at week 0 throughout the remainder of the study, including the periods when the drug was not being administered. At week 20, the end of the third period of drug administration, the patients receiving tobramycin had an average 10 percent increase in FEV1, as compared with a 2 percent decline in the patients receiving placebo (P<0.001) (Figure 1Figure 1
Mean Change in the Forced Expiratory Volume in One Second (FEV1) in Patients Receiving Inhaled Tobramycin or Placebo.). Multiple-regression analysis showed that treatment group, age, and severity of disease were significant predictors of changes in FEV1; sex, highest MIC of tobramycin, and use of dornase alfa were not. Improvements in forced vital capacity in the tobramycin group were similar to those in FEV1 (data not shown), with an average increase of 8 percent from week 0 to week 20, as compared with a 1 percent decline in the placebo group.Microbial Response
The density of P. aeruginosa in sputum samples from the tobramycin-treated patients decreased during each of the three 28-day periods when the drug was administered and approached week 0 values during the periods when the drug was withheld (Figure 2Figure 2
Mean Change in the Density of P. aeruginosa in Samples of Expectorated Sputum.). The treatment effects were greatest during the first two treatment cycles, with an average reduction of 2.2 log10 CFU per gram of sputum at week 2, 1.9 log10 CFU per gram at week 4, and 1.8 log10 CFU per gram at week 12. By the end of the third period of drug administration (week 20), there was an average reduction of 0.8 log10 CFU per gram of sputum, as compared with the value at week 0, whereas the density in the placebo group had increased by 0.3 log10 CFU per gram (P<0.001). Resistance to tobramycin associated with drug administration did not account for the diminished microbial reduction in the third cycle (Figure 2).Hospitalization and Intravenous-Antibiotic Use
The patients receiving tobramycin were 26 percent (95 percent confidence interval, 2 to 43 percent) less likely to be hospitalized and 36 percent (95 percent confidence interval, 17 to 51 percent) less likely to require intravenous antipseudomonal antibiotics than the patients receiving placebo. The patients in the tobramycin group received intravenous antipseudomonal antibiotics for an average of 9.6 days and were hospitalized for an average of 5.1 days. Thirty-nine percent of the patients receiving tobramycin (100 of 258) received one or more courses of intravenous antibiotics, and 37 percent (95 of 258) were hospitalized at least once. The patients in the placebo group received intravenous antipseudomonal antibiotics for an average of 14.1 days and were hospitalized for an average of 8.1 days. Fifty-two percent of the patients receiving placebo (135 of 262) received one or more courses of intravenous antipseudomonal antibiotics, and 45 percent (117 of 262) were hospitalized at least once.
Subgroup Analyses
In each subgroup of patients (defined on the basis of age, sex, disease severity, and use or nonuse of dornase alfa), the FEV1 increased from week 0 to week 20 in the patients receiving tobramycin and decreased in those receiving placebo (Table 2Table 2
Change in FEV1 from Week 0 to Week 20 According to Subgroup.). The one exception was an increase in FEV1 in patients receiving placebo who were 6 to 12 years old. The difference in the change in FEV1 between the treatment groups was significant in all subgroups except that of patients 6 to 12 years old (P=0.08).Subgroup–treatment interactions were examined to determine whether the effect of inhaled tobramycin differed among the subgroups. There was no significant difference in the improvement achieved with inhaled tobramycin according to sex, disease severity, or use or nonuse of dornase alfa. However, patients who were 13 to 17 years old had a significantly greater increase in FEV1 than those who were younger or older. The effect of treatment on P. aeruginosa density was also influenced by age, with the effect decreasing with increasing age (P=0.01, data not shown).
Adverse Events
Tinnitus and alteration of the voice were the only adverse events that were reported in a significantly greater percentage of the tobramycin group than in the placebo group. Tinnitus was reported by eight patients (3.1 percent) in the tobramycin group and by none of those in the placebo group (P=0.003). Tinnitus was transient, was mild or moderate in severity, and did not lead to withdrawal from the study. The number of episodes did not increase with increasing cycles of drug administration, and no hearing loss was documented on audiograms. Voice alteration was reported by 33 patients (12.8 percent) in the tobramycin group and by 17 (6.5 percent) in the placebo group (P=0.02). Voice alteration was minimal in most cases and did not increase with subsequent cycles of drug administration or lead to withdrawal from the study.
Hemoptysis occurred in 69 patients (26.7 percent) in the tobramycin group and in 81 (30.9 percent) in the placebo group. Pneumothorax occurred in one patient in the tobramycin group and in four in the placebo group. Four patients in the placebo group died during the study (in all cases, the cause of death was the underlying illness); none of the tobramycin-treated patients died.
Tobramycin and Creatinine Levels
Serum tobramycin levels were measured at the estimated time of the peak concentration, one hour after the inhaled dose (TDX, Abbott, Abbott Park, Ill.; detectable level, ≥0.18 μg per milliliter). These data were not disclosed to the study centers. Patients receiving concomitant intravenous tobramycin were excluded from this analysis. In the tobramycin group, the median serum level after the first dose had been administered was 0.94 μg per milliliter (range, 0.18 to 3.62). At week 20, the median serum level was 0.98 μg per milliliter (range, 0.18 to 3.41).
In the tobramycin group, the mean creatinine values were 0.91 mg per deciliter (80.44 μmol per liter) at week 0 and 0.89 mg per deciliter (78.68 μmol per liter) at week 20. In the placebo group, the mean creatinine values were 0.88 mg per deciliter (77.79 μmol per liter) at week 0 and 0.87 mg per deciliter (76.91 μmol per liter) at week 20. Nine patients in each group had transient increases of 50 percent or more in the creatinine value.
Audiologic Studies
Serial audiologic testing was performed in 302 patients (148 in the tobramycin group and 154 in the placebo group). No patients had hearing loss according to the prospectively defined criteria.
Bronchospasm
At week 0, the median change in FEV1 30 minutes after the first dose of the study drug had been administered was –1.8 percent (range, –34.4 to +21.1) in the tobramycin group and –2.6 percent (range, –43.6 to +34.1) in the placebo group. At week 20, the median change in FEV1 was –2.0 percent (range, –29.8 to +77.7) in the tobramycin group and –2.0 percent (range, –24.0 to +38.4) in the placebo group.
Microbiologic Findings
There was a trend toward an increase in the MIC of tobramycin in the P. aeruginosa isolates from the patients receiving tobramycin but not in the isolates from the patients receiving placebo (Figure 3Figure 3
Changes in the Minimal Inhibitory Concentration (MIC) of Tobramycin in P. aeruginosa Isolates from Patients in the Tobramycin Group (Upper Panel) and the Placebo Group (Lower Panel).). The proportion of tobramycin-treated patients with P. aeruginosa isolates for which the MIC was at least 8 μg per milliliter increased from 25 percent (63 of 254 patients) at week 0 to 32 percent (72 of 224) at week 24, as compared with 20 percent (51 of 254 patients) at week 0 and 17 percent (38 of 223) at week 24 in the placebo group. A total of 171 patients in the tobramycin group had P. aeruginosa isolates for which the MIC was 4 μg or less per milliliter; in this group, the mean improvement in FEV1 was 11 percent (95 percent confidence interval, –35 to +57 percent) at week 20 as compared with the value at week 0. In the 58 patients who had isolates for which the MIC was 8 μg or more per milliliter, the FEV1 increased by 8 percent from week 0 to week 20 (95 percent confidence interval, –34 to +50 percent).B. cepacia was newly isolated from respiratory tract secretions in two patients in the tobramycin group and three in the placebo group during the study. Stenotrophomonas maltophilia was newly isolated from respiratory tract secretions in 41 patients in the tobramycin group and 58 in the placebo group.
Discussion
Our study shows that long-term, intermittent administration of inhaled tobramycin in conjunction with standard therapy for cystic fibrosis improves pulmonary function, decreases the density of P. aeruginosa in expectorated sputum, and reduces the need for intravenous antipseudomonal antibiotics and hospitalization. Pulmonary function is the best predictor of morbidity and mortality in patients with cystic fibrosis and is the most widely used clinical end point in therapeutic trials.13,14 Treatment with tobramycin improved lung function in all subgroups defined at the start of the study on the basis of age, sex, severity of lung disease, and concurrent use or nonuse of dornase alfa. The improvement in patients using dornase alfa suggests that tobramycin has an additive effect.15
We used bacterial density in sputum as a long-term microbiologic end point. The decrease of 1 to 2 log10 (i.e., 90 to 99 percent bactericidal activity) in the density of P. aeruginosa in sputum during the first two treatment cycles is similar to the bactericidal effect reported in a previous study of high-dose inhaled tobramycin8 after 28 days of therapy. During each period when the drug was not being used, the improvement in lung function was maintained, whereas the density of P. aeruginosa in sputum returned toward base-line values. In addition, the magnitude of bacterial reduction was smaller with the third cycle of therapy, although the improvement in lung function was maintained. Resistance to tobramycin during treatment was not responsible for this reduction in the antimicrobial effect. Follow-up studies will determine whether the reduced bactericidal effect in the third cycle is a harbinger of reduced lung function in subsequent cycles of therapy. However, an interim analysis of a subgroup of 128 patients treated with this regimen for 11 months has shown that the improvement in lung function is maintained (increase in FEV1 at week 44 as compared with week 0, 9.8 percent; data not shown). These findings suggest that, in addition to its known bactericidal activity, inhaled tobramycin may have an antiinflammatory effect or may inhibit the production of factors that influence the virulence of pseudomonas,16 allowing improved lung function even with smaller reductions in the density of P. aeruginosa.
The role of inhaled antibiotics in altering the susceptibility of airway microbes to antibiotics is an important clinical issue. In our studies, the proportion of tobramycin-treated patients who had P. aeruginosa isolates for which the MIC was at least 8 μg per milliliter increased from 25 percent to 32 percent over a period of 24 weeks. In comparison, the proportion of patients treated with intravenous tobramycin for 14 days who had isolates for which the MIC was at least 8 μg per milliliter increased from 29 to 43 percent.17 Our rationale for intermittent administration of tobramycin was based on the observation that “drug holidays” allow susceptible pathogens to repopulate the airways in patients with cystic fibrosis.18 The threshold of susceptibility to tobramycin with parenteral therapy may not be relevant to inhalational therapy, since the concentration of inhaled drug can be 100 times as high as the systemic concentration. In our patients treated with inhaled tobramycin, the improvement in FEV1 at week 20 was similar whether the MIC of tobramycin in P. aeruginosa isolates was above or below the threshold of susceptibility to the drug when it is administered parenterally.
In our studies, tobramycin was administered by means of a jet nebulizer (mean particle size, 4 μm). This device was chosen to deliver the drug to the site of infection in the airways rather than the alveoli. Minimizing delivery to the alveolar surface area may help limit systemic absorption.19 The formulation of tobramycin that we used did not increase airway reactivity. In contrast, preparations intended for intravenous use may contain phenol or metabisulfites, which are known to irritate the airways.20 The results with the drug–nebulizer combination we used may not be applicable to other formulations or devices, and other devices have not been formally tested.
The widespread use of antibiotic therapy since the 1940s for lung infections in patients with cystic fibrosis has contributed to improvement in survival.21 The use of inhaled tobramycin in combination with current treatment for patients with cystic fibrosis who have P. aeruginosa infection with airway obstruction may provide an additional benefit. Further refinements in treatment, such as optimizing the regimens of current antibiotics, developing new antibiotics, and developing new modes of delivery, may result in even greater benefits in the future for patients with cystic fibrosis.
Supported by grants from the National Institutes of Health (P30-DK47754, MO1, RR-00037, and HL 50253), the Cystic Fibrosis Foundation (RDP R565-5527), and the Food and Drug Administration (Orphan Products Grant FD-R-001235-01).
Drs. Ramsey, Montgomery, and Smith hold a patent for the formulation of tobramycin used in the study. PathoGenesis, where Dr. Montgomery, Dr. Quan, Ms. Otto, and Mr. Vasiljev-K are employees, has licensed this invention through Children's Hospital and Regional Medical Center in Seattle, which owns Drs. Smith and Ramsey's contributions to the invention.
We are indebted to the members of the Data and Safety Monitoring Board for their careful oversight of the studies: Drs. Michael Knowles (chairman), David Speert, Lloyd Fisher, and John Slattery; to Drs. Robert Beall and Stacy FitzSimmons of the Cystic Fibrosis Foundation for their support; to the microbiology-laboratory technicians at Children's Hospital Regional Medical Center for performing the microbiologic studies; to the clinical-program staff at PathoGenesis; to Heather Drennan, Tanya Desloover, and Uta Meyer for assistance in the preparation of the manuscript; and most important, to the patients and parents who volunteered to participate in the study.
Source Information
From the Department of Pediatrics, University of Washington School of Medicine, Seattle (B.W.R., J.W.-W., S.M.); the Department of Biostatistics, University of Washington School of Public Health, Seattle (M.S.P.); PathoGenesis, Seattle (J.M.Q., K.L.O., A.B.M., M.V.); the Department of Pediatrics, State University of New York, Buffalo, N.Y. (D.B.); the Department of Pediatrics, University of Southern California, Los Angeles (C.M.B.); the Department of Medicine, University of Utah, Salt Lake City (B.C.M.); and the Department of Molecular Microbiology, University of Missouri School of Medicine, Columbia (A.L.S.).
Address reprint requests to Dr. Ramsey at Children's Hospital and Regional Medical Center, CH-18, P.O. Box C-5371, Seattle, WA 98105.
Other members of the Cystic Fibrosis Inhaled Tobramycin Study Group are listed in the Appendix.
Appendix
In addition to the authors, the following investigators participated in the Cystic Fibrosis Inhaled Tobramycin Study Group: Writing Committee — M. Aitken, G. Albers, S. Fiel, G. Marelich, T. Murphy, N. Eid, H.W. Parker, J. Van Dalfsen, and B. Nickerson; Children's Hospital and Regional Medical Center — J. Burns, T. Standaert, C. Clausen, M. Cohen, and S. McNamara; participating investigators — I. Abdulhamid and C. Van Wagnen, Children's Hospital of Michigan; A. Adler and P. Tosta, Children's Hospital, Oakland; G. Albers and P. Lewis, Saint Louis University–Cardinal Glennon Children's Hospital; S. Aronoff and L. Baer, West Virginia University; J. Biller and M. Freeman, Children's Hospital of Wisconsin, Medical College of Wisconsin; M. Harris, Children's Hospital of Buffalo; L. Auw, Children's Hospital, Los Angeles; D. Caplan, D. Gilbert, and R. Borner, Emory University School of Medicine; M. Chernick, L. Guthrie, and Y. Park, National Institutes of Health; A. Cohen, D. Rosenbluth, and M. Boyle, Washington University; S. Davis and P. DeWitt, Tulane University School of Medicine; J. Decelie-Germana and C. Grece, St. Vincent's Hospital and Medical Center; R. Diaz and T. Brascia, University of Nevada School of Medicine; G. do Pico and S. Wilson, University of Wisconsin; A. Dove and L. Ward, Santa Rosa Children's Hospital; M. Dyson and J. Garbarz, Cook–Fort Worth Children's Medical Center; N. Eid and M. Eddy, University of Louisville; H. Eigen, M. Blagburn, and D. Terrill, Indiana University Medical Center–Riley Hospital; J. Eisenberg and S. Rae, Oregon Health Sciences University; S. Fiel and B. Levin, Medical College of Pennsylvania; R. Fink and J. Kluft, Children's National Medical Center; R. Gerstle and A. Pellett, Baystate Medical Center; M. Guill and W. Andrews, Medical College of Georgia; P. Hiatt, R. Schwalm, and D. Treece, Baylor College of Medicine–Texas Children's Hospital; B. Hilman and A. Gardner, Louisiana State University Medical Center; R. Honicky and K. King, Michigan State University; D. Iannuzzi and D. Lindner, SUNY Health Science Center; S. Inscore, J. Schmidt, and K. Batzer, Brooke Army Medical Center; J. Kanga and L. Cragimyle, University of Kentucky College of Medicine; R. Kishore and S. Lederman, Children's Hospital Medical Center of Akron; P. Konig and J. Poehler, University of Missouri Hospital and Clinics; A. Lapey and K. Chervinsky, Massachusetts General Hospital; J. Lieberman, H. Stutman, and N. O'Donnell, Memorial Miller Children's Hospital; M. Light and A. Ashinger, University of California at San Diego Medical Center; F. Livingston, J. Chiaro, M. James, and K. Rinker, Arnold Palmer Children's Hospital; M. Majure and R. Qualls, Duke University Medical Center; A. Mansell and P. Marciniak, Rhode Island Hospital; G. Marelich, N. Couper, and B. Yule, University of California, Davis; C. Pope, University of Utah Health Sciences Center; M. Aitken, S. McNamara, and P. Joy, Children's Hospital and Regional Medical Center, Seattle; M. McCarthy and K. Harrington, Deaconess Medical Center; B. McWilliams, D. Hunt, and M. Braun, University of New Mexico; R. Moss, Z. Davies, and A. Harkins, Lucile S. Packard Children's Hospital at Stanford; T. Murphy and E. Hartigan, University of Pittsburgh–Children's Hospital of Pittsburgh; S. Nasr and E. Sakmar, University of Michigan; B. Nickerson, M. Hendricks, and G. Gonzales, Children's Hospital of Orange County; R. Palazzo, C. Tolomeo, S. Zanker, and C. Guandalini, Yale University School of Medicine; W. Parker and M. Stamowlaros, Dartmouth–Hitchcock Medical Center; R. Parry and K. Knippling, University of South Dakota School of Medicine; C. Prestidge, M. Brown, R. Rosenblatt, and K. Smith, Cystic Fibrosis Care and Teaching Center, Dallas; L. Quittell and L. Andersen, Columbia University College of Physicians and Surgeons; P. Radford and J. Harris, Phoenix Children's Hospital; W. Regelmann, C. Milla, and J. Zirbes, University of Minnesota; C. Ren, K. Patel, and T. Carney, University Hospital and Children's Medical Center at Stony Brook; G. Retsch-Bogart and K. Hohneker, University of North Carolina; S. Reyes de la Rocha and S. Washa, Lynn Health Science Institute; D. Roberts and J. Minarik, Providence Alaska Medical Center; W. Robinson, C. Dansereau, and C. Thayer, Children's Hospital, Boston; B. Rosenstein and A. Austin, Johns Hopkins Hospital; D. Schidlow, S. Graves, and K. Hyman (deceased), St. Christopher's Hospital for Children; P. Shaw and R. Leff, University of Kansas Medical Center; G. Shay and E. Högvall, Kaiser Permanente Medical Care Program, Northern California region; L. Sindel and K. Smith, Pulmonary Association of Mobile; M. Stulbarg, D. Conrad, and D. Lallas, University of California, San Francisco; N. Turcios and T. Philogene, University of Medicine and Dentistry of New Jersey–New Jersey Medical School; B. Varma, L. Tkatch, and K. Bynum, Polyclinic Medical Center; K. Voter, D. Toder, R. Sierzega, and S. Wilson, University of Rochester Medical Center–Strong Memorial Hospital; R. Wilmott and V. Kociela, Children's Hospital Medical Center, Cincinnati; W. Yee and J. McNamara, New England Medical Center–Floating Hospital for Children.
- References
References
1
Turpin SV, Knowles MR. Treatment of pulmonary disease in patients with cystic fibrosis. In: Davis PB, ed. Cystic fibrosis. Vol. 64 of Lung biology in health and disease. New York: Marcel Dekker, 1993:277-344.
2
Cystic Fibrosis Foundation patient registry 1996 annual data report. Bethesda, Md.: Cystic Fibrosis Foundation, 1997.
3
Fitzsimmons SC . The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9
Web of Science | Medline4
Hodson ME ,Penketh AR ,Batten JC . Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981;2:1137-1139
CrossRef | Web of Science | Medline5
Wall MA ,Terry AB ,Eisenberg J ,McNamara M ,Cohen R . Inhaled antibiotics in cystic fibrosis. Lancet 1983;1:1325-1325
CrossRef | Web of Science | Medline6
Steinkamp G ,Tummler B ,Gappa M , et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6:91-98
CrossRef | Web of Science | Medline7
MacLusky IB ,Gold R ,Corey M ,Levison H . Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-48
CrossRef | Web of Science | Medline8
Ramsey BW ,Dorkin HL ,Eisenberg JD , et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-1746
Full Text | Web of Science | Medline9
Eisenberg J ,Pepe M ,Williams-Warren J , et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997;111:955-962
CrossRef | Web of Science | Medline10
American Thoracic Society
Web of Science | Medline11
Knudson RJ ,Lebowitz MD ,Holberg CJ ,Burrows B . Changes in the normal maximal expiratory flow-volume curve with growing and aging. Am Rev Respir Dis 1983;127:725-734
Web of Science | Medline12
Burns JL ,Emerson J ,Stapp JR , et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163
CrossRef | Web of Science | Medline13
Kerem E ,Reisman J ,Corey M ,Canny GJ ,Levison H . Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-1191
Full Text | Web of Science | Medline14
Ramsey BW ,Boat TF . Outcome measures for clinical trials in cystic fibrosis: summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr 1994;124:177-192
CrossRef | Web of Science | Medline15
Fuchs HJ ,Borowitz DS ,Christiansen DH , et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642
Full Text | Web of Science | Medline16
Grimwood K ,Semple RA ,Rabin HR ,Sokol PA ,Woods DE . Elevated exoenzyme expression by Pseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis. Pediatr Pulmonol 1993;15:135-139
CrossRef | Web of Science | Medline17
Thomassen MJ ,Demko CA ,Boxerbaum B ,Stern RC ,Kuchenbrod PJ . Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis 1979;140:873-880
CrossRef | Web of Science | Medline18
Gilligan PH . Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991;4:35-51
Web of Science | Medline19
Wolff RK ,Niven RW . Generation of aerosolized drugs. J Aerosol Med 1994;7:89-106
CrossRef | Web of Science | Medline20
Dalton-Bunnow MF . Review of sulfite sensitivity. Am J Hosp Pharm 1985;42:2220-2226
Medline21
Davis PB ,Drumm M ,Konstan MW . Cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-1256
Web of Science | Medline
- Citing Articles (283)
Citing Articles
1
Donald R VanDevanter, Michael W Konstan. (2012) Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clinical Investigation 2:2, 163-175
CrossRef2
Meenakshi Bothra, Rakesh Lodha, Sushil Kumar Kabra. (2012) Tobramycin for the treatment of bacterial pneumonia in children. Expert Opinion on Pharmacotherapy1-7
CrossRef3
R.P. Aquino, L. Prota, G. Auriemma, A. Santoro, T. Mencherini, G. Colombo, P. Russo. (2012) Dry powder inhalers of gentamicin and leucine: Formulation parameters, aerosol performance and in vitro toxicity on Cufi1 cells. International Journal of Pharmaceutics
CrossRef4
Debra A. Wertz, Chun-Lan Chang, Judith J. Stephenson, Jie Zhang, Robert J. Kuhn. (2011) Economic impact of tobramycin in patients with cystic fibrosis in a managed care population. Journal of Medical Economics 14:6, 759-768
CrossRef5
Gerard McCaughey, Matt McKevitt, J. Stuart Elborn, Michael M. Tunney. (2011) Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. Journal of Cystic Fibrosis
CrossRef6
J. Abbott, A. Holt, A.M. Morton, A. Hart, G. Milne, S.P. Wolfe, S.P. Conway. (2011) Patient indicators of a pulmonary exacerbation: Preliminary reports from school aged children map onto those of adults. Journal of Cystic Fibrosis
CrossRef7
Donald R. VanDevanter, Manfred Ballmann, Patrick A. Flume. (2011) Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respiratory Medicine 105, S18-S23
CrossRef8
David Lo, Donald R. VanDevanter, Patrick Flume, Alan Smyth. (2011) Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?. Respiratory Medicine 105, S9-S17
CrossRef9
Manfred Ballmann, Alan Smyth, David E. Geller. (2011) Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. Respiratory Medicine 105, S2-S8
CrossRef10
Ramsey, Bonnie W., Davies, Jane, McElvaney, N. Gerard, Tullis, Elizabeth, Bell, Scott C., Dřevínek, Pavel, Griese, Matthias, McKone, Edward F., Wainwright, Claire E., Konstan, Michael W., Moss, Richard, Ratjen, Felix, Sermet-Gaudelus, Isabelle, Rowe, Steven M., Dong, Qunming, Rodriguez, Sally, Yen, Karl, Ordoñez, Claudia, Elborn, J. Stuart, . (2011) A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. New England Journal of Medicine 365:18, 1663-1672
Full Text11
Amélie Rognon, Christophe Curti, Marc Montana, Thierry Terme, Pascal Rathelot, Patrice Vanelle. (2011) Efficacité et avenir de l’aérosolthérapie dans le traitement des infections à Pseudomonas aeruginosa chez les patients atteints de mucoviscidose. Thérapie 66:6, 481-491
CrossRef12
Michael D Parkins, J Stuart Elborn. (2011) Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Review of Respiratory Medicine 5:5, 609-622
CrossRef13
Emer P. Reeves, David A. Bergin, Sean Fitzgerald, Elaine Hayes, Joanne Keenan, Michael Henry, Paula Meleady, Isabel Vega-Carrascal, Michelle A. Murray, Teck Boon Low, Cormac McCarthy, Emmet O'Brien, Martin Clynes, Cedric Gunaratnam, Noel G. McElvaney. (2011) A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis
CrossRef14
Ryan Hudson, Brooke Olson Blair. (2011) Inhaled antibiotics for Gram-negative respiratory infections. Future Medicinal Chemistry 3:13, 1663-1677
CrossRef15
N. A. Jarad, I. M. Sequeiros. (2011) A novel respiratory symptom scoring system for CF pulmonary exacerbations. QJM
CrossRef16
Shuang Ji, Limin Peng, Yu Cheng, HuiChuan Lai. (2011) Quantile Regression for Doubly Censored Data. Biometricsno-no
CrossRef17
Franziska A. Stressmann, Geraint B. Rogers, Peter Marsh, Andrew K. Lilley, Thomas W.V. Daniels, Mary P. Carroll, Lucas R. Hoffman, Graeme Jones, Collette E. Allen, Nilesh Patel, Benjamin Forbes, Andrew Tuck, Kenneth D. Bruce. (2011) Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?. Journal of Cystic Fibrosis 10:5, 357-365
CrossRef18
Lucy B. Palmer. (2011) Aerosolized Antibiotics in the Intensive Care Unit. Clinics in Chest Medicine 32:3, 559-574
CrossRef19
C. Nagant, Y. Feng, B. Lucas, K. Braeckmans, P. Savage, J.P. Dehaye. (2011) Effect of a low concentration of a cationic steroid antibiotic (CSA-13) on the formation of a biofilm by Pseudomonas aeruginosa. Journal of Applied Microbiology 111:3, 763-772
CrossRef20
David E. Geller, Jeffry Weers, Silvia Heuerding. (2011) Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology. Journal of Aerosol Medicine and Pulmonary Drug Delivery 24:4, 175-182
CrossRef21
Reshma Amin, Valerie Waters, Reshma Amin. 2011. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. .
CrossRef22
Arvind Venkat, Joseph M. Pilewski. 2011. Adults with Cystic Fibrosis. , 96-114.
CrossRef23
Michelle N. Eakin, Andrew Bilderback, Michael P. Boyle, Peter J. Mogayzel, Kristin A. Riekert. (2011) Longitudinal association between medication adherence and lung health in people with cystic fibrosis. Journal of Cystic Fibrosis 10:4, 258-264
CrossRef24
D.R. VanDevanter, A. Yegin, W.J. Morgan, S.J. Millar, D.J. Pasta, M.W. Konstan. (2011) Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. Journal of Cystic Fibrosis
CrossRef25
Geraint B. Rogers, Lucas R. Hoffman, Gerd Döring. (2011) Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. Journal of Cystic Fibrosis
CrossRef26
D. Bilton, G. Canny, S. Conway, S. Dumcius, L. Hjelte, M. Proesmans, B. Tümmler, V. Vavrova, K. De Boeck. (2011) Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. Journal of Cystic Fibrosis 10, S79-S81
CrossRef27
Fatih Oghan, Tayfun Apuhan, Fahrettin Yılmaz. (2011) Ototoxicity caused by topical administration of gentamicin versus tobramycin in rabbits. International Journal of Pediatric Otorhinolaryngology
CrossRef28
Shigeki Nakamura, Katsunori Yanagihara, Nobuko Araki, Koichi Yamada, Yoshitomo Morinaga, Koichi Izumikawa, Masafumi Seki, Hiroshi Kakeya, Yoshihiro Yamamoto, Shimeru Kamihira, Shigeru Kohno. (2011) High-dose tobramycin inhibits lipopolysaccharide-induced MUC5AC production in human lung epithelial cells. European Journal of Pharmacology 659:1, 67-71
CrossRef29
Allan L. Coates, Oliver Denk, Kitty Leung, Nancy Ribeiro, Jeffrey Chan, Maria Green, Sean Martin, Martin Charron, Michael Edwardes, Manfred Keller. (2011) Higher Tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Pediatric Pulmonology 46:4, 401-408
CrossRef30
Greg L. Plosker. (2011) Aztreonam Lysine for Inhalation Solution in Cystic Fibrosis†. Pediatric Drugs 13:2, 129-131
CrossRef31
Rebecca Ryan, Sophie Hill, Dianne Lowe, Kelly Allen, Michael Taylor, Cathy Mead, Rebecca Ryan. 2011. Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) (or other prion diseases) through medical treatment (iatrogenically). .
CrossRef32
Gerard Ryan, Meenu Singh, Kerry Dwan, Gerard Ryan. 2011. Inhaled antibiotics for long-term therapy in cystic fibrosis. .
CrossRef33
Laurent Vecellio, Mohamed E. Abdelrahim, Jerome Montharu, Julien Galle, Patrice Diot, Jean-Christophe Dubus. (2011) Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin. Journal of Cystic Fibrosis 10:2, 86-92
CrossRef34
Anne Stephenson, Janet Hux, Elizabeth Tullis, Peter C. Austin, Mary Corey, Joel Ray. (2011) Higher risk of hospitalization among females with cystic fibrosis. Journal of Cystic Fibrosis 10:2, 93-99
CrossRef35
Michael W. Konstan, David E. Geller, Predrag Minić, Florian Brockhaus, Jie Zhang, Gerhild Angyalosi. (2011) Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatric Pulmonology 46:3, 230-238
CrossRef36
David Berlana, Josep Manel Llop, Frederic Manresa, Ramón Jódar. (2011) Outpatient Treatment of Pseudomonas aeruginosa Bronchial Colonization with Long-term Inhaled Colistin, Tobramycin, or Both in Adults without Cystic Fibrosis. Pharmacotherapy 31:2, 146-157
CrossRef37
Samuel M. Moskowitz, Julia C. Emerson, Sharon McNamara, Richard D. Shell, David M. Orenstein, Daniel Rosenbluth, Marcia F. Katz, Richard Ahrens, Douglas Hornick, Patricia M. Joseph, Ronald L. Gibson, Moira L. Aitken, Wade W. Benton, Jane L. Burns. (2011) Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatric Pulmonology 46:2, 184-192
CrossRef38
Rosa M. Girón Moreno, Antonio Salcedo Posadas, Rosa Mar Gómez-Punter. (2011) Antibioterapia inhalada en la fibrosis quística. Archivos de Bronconeumología 47, 14-18
CrossRef39
Niels Høiby. (2011) Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Medicine 9:1, 32
CrossRef40
Michael W. Konstan, Patrick A. Flume, Matthias Kappler, Raphaël Chiron, Mark Higgins, Florian Brockhaus, Jie Zhang, Gerhild Angyalosi, Ellie He, David E. Geller. (2011) Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Journal of Cystic Fibrosis 10:1, 54-61
CrossRef41
Miguel Ángel Martínez García, Juan José Soler Cataluña, Pablo Catalán Serra. (2011) Antibióticos inhalados en el tratamiento de las bronquiectasias no debidas a fibrosis quística. Archivos de Bronconeumología 47, 19-23
CrossRef42
Montserrat Vendrell Relat, Gerard Muñoz Castro, Gladis Sabater Talaverano, Javier De Gracia Roldán. (2011) El futuro de la antibioterapia inhalada. Nuevos productos. Archivos de Bronconeumología 47, 30-32
CrossRef43
Lynne G. Maxwell, Salvatore R. Goodwin, Thomas J. Mancuso, Victor C. Baum, Aaron L. Zuckerberg, Philip G. Morgan, Etsuro K. Motoyama, Peter J. Davis, Kevin J. Sullivan. 2011. Systemic Disorders. , 1098-1182.
CrossRef44
Warren Lenney, Frank Edenborough, Pearl Kho, John M. Kovarik. (2011) Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. Journal of Cystic Fibrosis 10:1, 9-14
CrossRef45
Félix Baranda, Ainhoa Gómez, Beatriz Gómez. (2011) Antibioterapia inhalada en otras enfermedades respiratorias. Archivos de Bronconeumología 47, 24-29
CrossRef46
Gregory S. Sawicki, James E. Signorovitch, Jie Zhang, Dominick Latremouille-Viau, Markus von Wartburg, Eric Q. Wu, Lizheng Shi. (2011) Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatric Pulmonologyn/a-n/a
CrossRef47
L. M. Rose, R. Neale. (2010) Development of the First Inhaled Antibiotic for the Treatment of Cystic Fibrosis. Science Translational Medicine 2:63, 63mr4-63mr4
CrossRef48
Giuseppe Valenza, Kerstin Radike, Christoph Schoen, Stephan Horn, Anett Oesterlein, Matthias Frosch, Marianne Abele-Horn, Helge Hebestreit. (2010) Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment. Scandinavian Journal of Infectious Diseases 42:11-12, 885-889
CrossRef49
J. Rademacher, M.W. Pletz, T. Welte. (2010) Behandlung nicht mit zystischer Fibrose assoziierter Bronchiektasen (Non-CF-Bronchiektasen). Der Internist 51:12, 1510-1515
CrossRef50
Christopher M. Oermann, George Z. Retsch-Bogart, Alexandra L. Quittner, Ronald L. Gibson, Karen S. McCoy, A. Bruce Montgomery, Peter J. Cooper. (2010) An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatric Pulmonology 45:11, 1121-1134
CrossRef51
Niels Høiby, Oana Ciofu, Thomas Bjarnsholt. (2010) Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiology 5:11, 1663-1674
CrossRef52
Greg L. Plosker. (2010) Aztreonam Lysine for Inhalation Solution. Drugs 70:14, 1843-1855
CrossRef53
M.W. Konstan, J.S. Wagener, A. Yegin, S.J. Millar, D.J. Pasta, D.R. VanDevanter. (2010) Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint. Journal of Cystic Fibrosis 9:5, 332-338
CrossRef54
Christopher D Sibley, Margot E Grinwis, Harvey R Rabin, Michael G Surette. (2010) Azithromycin paradox in the treatment of cystic fibrosis airway disease. Future Microbiology 5:9, 1315-1319
CrossRef55
Michael D Parkins, J Stuart Elborn. (2010) Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis. Expert Review of Respiratory Medicine 4:4, 435-444
CrossRef56
2010. Implications of Biofilm Formation in Chronic Wounds and in Cystic Fibrosis. , 226-263.
CrossRef57
E.L. Guy, M. Bosomworth, M. Denton, S.P. Conway, K.G. Brownlee, T.W.R. Lee. (2010) Serum tobramycin levels following delivery of tobramycin (Tobi®) via eFlow® advanced nebuliser in children with cystic fibrosis. Journal of Cystic Fibrosis 9:4, 292-295
CrossRef58
Jennifer Le, Elizabeth Dodds Ashley, Melinda M Neuhauser, Jack Brown, Chris Gentry, Michael E Klepser, Ann Marie Marr, Daryl Schiller, Joshua N Schwiesow, Sally Tice, Heather L VandenBussche, G. Christopher Wood. (2010) Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria. Pharmacotherapy 30:6, 562-584
CrossRef59
R.D. Gray, M. Imrie, A.C. Boyd, D. Porteous, J.A. Innes, A.P. Greening. (2010) Sputum and serum calprotectin are useful biomarkers during CF exacerbation. Journal of Cystic Fibrosis 9:3, 193-198
CrossRef60
ALEX GUERRA FERREIRA, ROBSON SOUZA LEÃO, ANA PAULA D’ALINCOURT CARVALHO-ASSEF, TANIA WROBEL FOLESCU, AFONSO LUÍS BARTH, ELIZABETH ANDRADE MARQUES. (2010) Influence of biofilm formation in the susceptibility of Pseudomonas aeruginosa from Brazilian patients with cystic fibrosis. APMISno-no
CrossRef61
John Denyer, Ivan Prince, Emma Dixon, Penny Agent, Jennifer Pryor, Margaret Hodson. (2010) Evaluation of the Target Inhalation Mode (TIM) Breathing Maneuver in Simulated Nebulizer Therapy in Patients with Cystic Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery 23:s1, S-29-S-36
CrossRef62
Sunny Sarfaraz, Zoe Sund, Nabil Jarad. (2010) Real-time, once-daily monitoring of symptoms and FEV 1 in cystic fibrosis patients - A feasibility study using a novel device. The Clinical Respiratory Journal 4:2, 74-82
CrossRef63
A. Michalopoulos, E. Papadakis. (2010) Inhaled Anti-infective Agents: Emphasis on Colistin. Infection 38:2, 81-88
CrossRef64
Robert C. Read. 2010. Bacterial Infections of the Lower Respiratory Tract. .
CrossRef65
Michael Hindle. 2010. Aerosol Drug Delivery. .
CrossRef66
Geraint B Rogers, Franziska A Stressmann, Alan W Walker, Mary P Carroll, Kenneth D Bruce. (2010) Lung infections in cystic fibrosis: deriving clinical insight from microbial complexity. Expert Review of Molecular Diagnostics 10:2, 187-196
CrossRef67
James L. Kreindler. (2010) Cystic fibrosis: Exploiting its genetic basis in the hunt for new therapies. Pharmacology & Therapeutics 125:2, 219-229
CrossRef68
Harm A.W.M. Tiddens, Scott H. Donaldson, Margaret Rosenfeld, Peter D. Paré. (2010) Cystic fibrosis lung disease starts in the small airways: Can we treat it more effectively?. Pediatric Pulmonology 45:2, 107-117
CrossRef69
Matthew E. Falagas, Argyris Michalopoulos, Eugenios I. Metaxas. (2010) Pulmonary drug delivery systems for antimicrobial agents: facts and myths. International Journal of Antimicrobial Agents 35:2, 101-106
CrossRef70
Andreas Hector, Matthias Kappler, Matthias Griese. (2010) In Vitro Inhibition of Neutrophil Elastase Activity by Inhaled Anti-Pseudomonas Antibiotics Used in Cystic Fibrosis Patients. Mediators of Inflammation 2010, 1-5
CrossRef71
Jessica E. Pittman, Elizabeth H. Calloway, Michelle Kiser, John Yeatts, Stephanie D. Davis, Mitchell L. Drumm, Michael S. Schechter, Margaret W. Leigh, Mary Emond, Annelies Van Rie, Michael R. Knowles. (2010) Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease. Pediatric Pulmonologyn/a-n/a
CrossRef72
K. E. N. Milne, I. M. Gould. (2010) Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. Journal of Antimicrobial Chemotherapy 65:1, 82-90
CrossRef73
Samya Z. Nasr, Ermelinda Sakmar, Emmanuel Christodoulou, Boris P. Eckhardt, Daniel S. Streetman, Peter J. Strouse. (2010) The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. Pediatric Pulmonologyn/a-n/a
CrossRef74
Julia Emerson, Sharon McNamara, Anne Marie Buccat, Kelly Worrell, Jane L. Burns. (2010) Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatric Pulmonologyn/a-n/a
CrossRef75
Edith T. Zemanick, J. Kirk Harris, Steven Conway, Michael W. Konstan, Bruce Marshall, Alexandra L. Quittner, George Retsch-Bogart, Lisa Saiman, Frank J. Accurso. (2010) Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy. Journal of Cystic Fibrosis 9:1, 1-16
CrossRef76
Alexander Chuchalin, Elena Amelina, Federico Bianco. (2009) Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. Pulmonary Pharmacology & Therapeutics 22:6, 526-532
CrossRef77
Julie L. Huffmyer, Keith E. Littlewood, Edward C. Nemergut. (2009) Perioperative Management of the Adult with Cystic Fibrosis. Anesthesia & Analgesia 109:6, 1949-1961
CrossRef78
Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi. (2009) Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: A review. Journal of Cystic Fibrosis 8:6, 361-369
CrossRef79
Pavan Muttil, Chenchen Wang, Anthony J. Hickey. (2009) Inhaled Drug Delivery for Tuberculosis Therapy. Pharmaceutical Research 26:11, 2401-2416
CrossRef80
Lucy B Palmer. (2009) Aerosolized antibiotics in critically ill ventilated patients. Current Opinion in Critical Care 15:5, 413-418
CrossRef81
Marie Tré-Hardy, Hamidou Traore, Naïma El Manssouri, Francis Vanderbist, Mario Vaneechoutte, Michel Jean Devleeschouwer. (2009) Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents 34:4, 370-374
CrossRef82
D. L. MacLeod, L. M. Barker, J. L. Sutherland, S. C. Moss, J. L. Gurgel, T. F. Kenney, J. L. Burns, W. R. Baker. (2009) Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. Journal of Antimicrobial Chemotherapy 64:4, 829-836
CrossRef83
Stephen Kirkby, Kimberly Novak, Karen McCoy. (2009) Update on antibiotics for infection control in cystic fibrosis. Expert Review of Anti-infective Therapy 7:8, 967-980
CrossRef84
Andrew M. Jones, Jennifer M. Helm. (2009) Emerging Treatments in Cystic Fibrosis. Drugs 69:14, 1903-1910
CrossRef85
Harry Heijerman, Elsbeth Westerman, Steven Conway, Daan Touw. (2009) Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. Journal of Cystic Fibrosis 8:5, 295-315
CrossRef86
Dominique Hubert, Sylvie Leroy, Raphaële Nove-Josserand, Marlène Murris-Espin, Laurent Mely, Stéphane Dominique, Bertrand Delaisi, Pearl Kho, John M Kovarik. (2009) Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis. Journal of Cystic Fibrosis 8:5, 332-337
CrossRef87
J. Abbott, A. Holt, A. Hart, A.M. Morton, L. MacDougall, M. Pogson, G. Milne, H.C. Rodgers, S.P. Conway. (2009) What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis. Journal of Cystic Fibrosis 8:5, 356-359
CrossRef88
Miguel Ángel Martínez García, Luis Máiz Carro, Javier de Gracia Roldán. (2009) Tratamiento de las bronquiectasias en el adulto. Medicina Clínica 133:11, 433-440
CrossRef89
C.H. Goss, T.C. Edwards, B.W. Ramsey, M.L. Aitken, D.L. Patrick. (2009) Patient-reported respiratory symptoms in cystic fibrosis. Journal of Cystic Fibrosis 8:4, 245-252
CrossRef90
Israel Amirav, Malena Cohen-Cymberknoh, David Shoseyov, Eitan Kerem. (2009) Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis. Paediatric Respiratory Reviews 10:2, 58-62
CrossRef91
J.S. Elborn, M. Hodson, C. Bertram. (2009) Implementation of European standards of care for cystic fibrosis — Control and treatment of infection. Journal of Cystic Fibrosis 8:3, 211-217
CrossRef92
Jonathan B. Zuckerman, Deborah E. Zuaro, B. Stephen Prato, Kathryn L. Ruoff, Rafal W. Sawicki, Hebe B. Quinton, Lisa Saiman. (2009) Bacterial contamination of cystic fibrosis clinics. Journal of Cystic Fibrosis 8:3, 186-192
CrossRef93
Chiara Parlati, Paolo Colombo, Francesca Buttini, Paul M. Young, Handoko Adi, Alaina J. Ammit, Daniela Traini. (2009) Pulmonary Spray Dried Powders of Tobramycin Containing Sodium Stearate to Improve Aerosolization Efficiency. Pharmaceutical Research 26:5, 1084-1092
CrossRef94
Luis Máiz, Adelaida Lamas, Ana Fernández-Olmos, Lucrecia Suárez, Rafael Cantón. (2009) Unorthodox long-term aerosolized ampicillin use for methicillin-susceptible Staphylococcus aureus lung infection in a cystic fibrosis patient. Pediatric Pulmonology 44:5, 512-515
CrossRef95
Charles-Edouard Luyt, Alain Combes, Ania Nieszkowska, Jean-Louis Trouillet, Jean Chastre. (2009) Aerosolized antibiotics to treat ventilator-associated pneumonia. Current Opinion in Infectious Diseases 22:2, 154-158
CrossRef96
Gregory J. Redding. (2009) Bronchiectasis in Children. Pediatric Clinics of North America 56:1, 157-171
CrossRef97
David E Geller. (2009) Aerosol Antibiotics in Cystic Fibrosis. Respiratory Care 54:5, 658-670
CrossRef98
Marie Tré-Hardy, Camille Macé, Naïma El Manssouri, Francis Vanderbist, Hamidou Traore, Michel Jean Devleeschouwer. (2009) Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. International Journal of Antimicrobial Agents 33:1, 40-45
CrossRef99
Lennert Slobbe, Eric Boersma, Bart J.A. Rijnders. (2008) Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: Data from a randomized placebo-controlled trial. Pulmonary Pharmacology & Therapeutics 21:6, 855-859
CrossRef100
Michael N Dudley, Jeff Loutit, David C Griffith. (2008) Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Current Opinion in Biotechnology 19:6, 637-643
CrossRef101
Amy L. Marcinkowski, Stephen Garoff, Robert D. Tilton, Joseph M. Pilewski, Timothy E. Corcoran. (2008) Postdeposition Dispersion of Aerosol Medications Using Surfactant Carriers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 21:4, 361-370
CrossRef102
Clement L. Ren. (2008) Cystic Fibrosis: Evolution from a Fatal Disease of Infancy with a Clear Phenotype to a Chronic Disease of Adulthood with Diverse Manifestations. Clinical Reviews in Allergy & Immunology 35:3, 97-99
CrossRef103
Samuel M. Moskowitz, James F. Chmiel, Darci L. Sternen, Edith Cheng, Ronald L. Gibson, Susan G. Marshall, Garry R. Cutting. (2008) Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genetics in Medicine 10:12, 851-868
CrossRef104
Montserrat Vendrell, Javier de Gracia, Casilda Olveira, Miguel Ángel Martínez, Rosa Girón, Luis Máiz, Rafael Cantón, Ramon Coll, Amparo Escribano, Amparo Solé. (2008) Diagnóstico y tratamiento de las bronquiectasias. Archivos de Bronconeumología 44:11, 629-640
CrossRef105
Raphaël Chiron, Y. Yaël Grumbach, Nga V.T. Quynh, Valia Verriere, Valérie Urbach. (2008) Lipoxin A4 and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy. Journal of Cystic Fibrosis 7:6, 463-468
CrossRef106
J.-C. Dubus, S. Ravilly. (2008) Aérosolthérapie dans la mucoviscidose. Revue des Maladies Respiratoires 25:8, 989-998
CrossRef107
Patrick A. Flume. (2008) A role for aerosolized antibiotics. Pediatric Pulmonology 43:S9, S29-S34
CrossRef108
Elin Nilsson, Anders Larsson, Hanne V. Olesen, Per-Erik Wejåker, Hans Kollberg. (2008) Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatric Pulmonology 43:9, 892-899
CrossRef109
Elsbeth M. Westerman, Anne H. De Boer, Daan J. Touw, Paul P.H. Le Brun, Albert C. Roldaan, Henderik W. Frijlink, Harry G.M. Heijerman. (2008) Aerosolization of Tobramycin (TOBI ® ) with the PARI LC PLUS ® Reusable Nebulizer: Which Compressor to Use? Comparison of the CR60 ® to the PortaNeb ® Compressor. Journal of Aerosol Medicine and Pulmonary Drug Delivery 21:3, 269-280
CrossRef110
Samuel M. Moskowitz, Stefanie J. Silva, Nicole Mayer-Hamblett, David J. Pasta, David R. Mink, Jenny A. Mabie, Michael W. Konstan, Jeffrey S. Wagener, . (2008) Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatric Pulmonology 43:9, 874-881
CrossRef111
Daniel N. Kim, Angeline A. Lazarus. (2008) Management of Bronchiectasis. Disease-a-Month 54:8, 540-546
CrossRef112
Stanley B Fiel. (2008) Aerosolized antibiotics in cystic fibrosis: current and future trends. Expert Review of Respiratory Medicine 2:4, 479-487
CrossRef113
Ibrahim Abdulhamid, Terri L Wise, Stephanie Andrews, Kevin Biglin, Victoria Tutag Lehr. (2008) Elevated Serum Tobramycin Concentrations After Treatment with Tobramycin Inhalation in a Preterm Infant. Pharmacotherapy 28:7, 939-944
CrossRef114
Clement L Ren. (2008) Assessment and monitoring of cystic fibrosis lung disease in infants and young children. Expert Review of Respiratory Medicine 2:3, 381-390
CrossRef115
Michael D. Tsifansky, Yoon Yeo, Oleg V. Evgenov, Evangelia Bellas, John Benjamin, Daniel S. Kohane. (2008) Microparticles for Inhalational Delivery of Antipseudomonal Antibiotics. The AAPS Journal 10:2, 254-260
CrossRef116
Jennifer R Weiner, Edmond L Toy, Patricia Sacco, Mei Sheng Duh. (2008) Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opinion on Pharmacotherapy 9:5, 751-766
CrossRef117
Marie Tré-Hardy, Francis Vanderbist, Hamidou Traore, Michel Jean Devleeschouwer. (2008) In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. International Journal of Antimicrobial Agents 31:4, 329-336
CrossRef118
David Nichols, James Chmiel, Melvin Berger. (2008) Chronic Inflammation in the Cystic Fibrosis Lung: Alterations in Inter- and Intracellular Signaling. Clinical Reviews in Allergy & Immunology 34:2, 146-162
CrossRef119
Stephan Ehrmann, Emmanuelle Mercier, Laurent Vecellio, David Ternant, Gilles Paintaud, Pierre-François Dequin. (2008) Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. Intensive Care Medicine 34:4, 755-762
CrossRef120
Jennifer Fiegel, Lucila Garcia-Contreras, Matthew Thomas, Jarod VerBerkmoes, Katharina Elbert, Anthony Hickey, David Edwards. (2008) Preparation and in Vivo Evaluation of a Dry Powder for Inhalation of Capreomycin. Pharmaceutical Research 25:4, 805-811
CrossRef121
M. Radhakrishnan, A. Jaganath, G.S. Umamaheswara Rao, H.B.Veena Kumari. (2008) Nebulized imipenem to control nosocomial pneumonia caused by Pseudomonas aeruginosa. Journal of Critical Care 23:1, 148-150
CrossRef122
C.H. Goss, E.F. McKone, D. Mathews, D. Kerr, J.S. Wanger, S.P. Millard. (2008) Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis. Journal of Cystic Fibrosis 7:2, 147-153
CrossRef123
Bruce K. Rubin. (2008) Aerosolized Antibiotics for Non-Cystic Fibrosis Bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery 21:1, 71-76
CrossRef124
Christopher H. Goss, Nicole Mayer-Hamblett, Judy Williams, Bonnie W. Ramsey. (2008) The Cystic Fibrosis Foundation Therapeutics Development Network: A National Effort by the Cystic Fibrosis Foundation to Build a Clinical Trials Network. Children's Health Care 37:1, 5-20
CrossRef125
Bruce K. Rubin. (2008) Aerosolized Antibiotics for Non-Cystic Fibrosis Bronchiectasis. Journal of Aerosol Medicine 0:0, 080208124710593-6
CrossRef126
Harm A.W.M. Tiddens, Margaret Rosenfeld. 2008. Respiratory Manifestations. , 871-887.
CrossRef127
Shin-Woo Kim, Joseph L. Kuti, David P. Nicolau. (2008) Inhaled antimicrobial therapies for respiratory infections. Current Infectious Disease Reports 10:1, 29-36
CrossRef128
George Z. Retsch-Bogart, Jane L. Burns, Kelly L. Otto, Theodore G. Liou, Karen McCoy, Christopher Oermann, Ronald L. Gibson, . (2008) A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis andPseudomonas aeruginosa infection. Pediatric Pulmonology 43:1, 47-58
CrossRef129
Joseph D. Spahn, Stanley J. Szefler. 2008. Pharmacology of the Lung and Drug Therapy. , 219-233.
CrossRef130
Iwona Stelmach, Aleksandra Korzeniewska, Włodzimierz Stelmach. (2008) Long-Term Benefits of Inhaled Tobramycin in Children with Cystic Fibrosis: First Clinical Observations from Poland. Respiration 75:2, 178-181
CrossRef131
C. Damas, A. Amorim, I. Gomes, V.P. Hespanhol. (2008) Fibrose quística: Revisão. Revista Portuguesa de Pneumologia (English Edition) 14:1, 89-112
CrossRef132
Anne Stone, Lisa Saiman. (2007) Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine 13:6, 515-521
CrossRef133
&NA;. (2007) Appropriate antibacterial therapy is crucial in the management of Pseudomonas aeruginosa infections. Drugs & Therapy Perspectives 23:10, 14-16
CrossRef134
Allan L. Coates, Maria Green, Kitty Leung, Emily Louca, Markus Tservistas, Jeffrey Chan, Nancy Ribeiro, Martin Charron. (2007) The Challenges of Quantitative Measurement of Lung Deposition Using 99m Tc-DTPA from Delivery Systems with Very Different Delivery Times. Journal of Aerosol Medicine 20:3, 320-330
CrossRef135
Eleanor Bates, Stacey Miller, Mariah Alexander, Marina Mazur, James A. Fortenberry, Zsuzsa Bebok, Eric J. Sorscher, Steven M. Rowe. (2007) Bioelectric effects of quinine on polarized airway epithelial cells. Journal of Cystic Fibrosis 6:5, 351-359
CrossRef136
M.A. Hasan, C.F. Lange. (2007) Estimating In Vivo Airway Surface Liquid Concentration in Trials of Inhaled Antibiotics. Journal of Aerosol Medicine 20:3, 282-293
CrossRef137
Salvador Bello Dronda, Manuel Vilá Justribó. (2007) ¿Seguiremos teniendo antibióticos mañana?. Archivos de Bronconeumología 43:8, 450-459
CrossRef138
Richard B. Moss, Carlos Milla, John Colombo, Frank Accurso, Pamela L. Zeitlin, John P. Clancy, L. Terry Spencer, Joseph Pilewski, David A. Waltz, Henry L. Dorkin, Thomas Ferkol, Mark Pian, Bonnie Ramsey, Barrie J. Carter, Dana B. Martin, Alison E. Heald. (2007) Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial. Human Gene Therapy 18:8, 726-732
CrossRef139
L Feldman, S Efrati, E Eviatar, R Abramsohn, I Yarovoy, E Gersch, Z Averbukh, J Weissgarten. (2007) Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney International 72:3, 359-363
CrossRef140
Thomas Lahiri. (2007) Approaches to the Treatment of Initial Pseudomonas aeruginosa Infection in Children Who Have Cystic Fibrosis. Clinics in Chest Medicine 28:2, 307-318
CrossRef141
Hebe B. Quinton, Gerald T. O'Connor. (2007) Current Issues in Quality Improvement in Cystic Fibrosis. Clinics in Chest Medicine 28:2, 459-472
CrossRef142
Myo-Kyoung Kim, David P. Nicolau. 2007. Aminoglycosides. , 147-176.
CrossRef143
Alicia M. Mohr, Ziad C. Sifri, Helen S. Horng, Ragui Sadek, Alisa Savetamal, Carl J. Hauser, David H. Livingston. (2007) Use of Aerosolized Aminoglycosides in the Treatment of Gram-Negative Ventilator-Associated Pneumonia. Surgical Infections 8:3, 349-358
CrossRef144
C. Damas, S. Saleiro, I. Gomes, J. Agostinho Marques. (2007) Fibrose quística em adultos. Revista Portuguesa de Pneumologia (English Edition) 13:3, 335-347
CrossRef145
David E. Geller, Michael W. Konstan, Jeffrey Smith, Sarah B. Noonberg, Carol Conrad. (2007) Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. Pediatric Pulmonology 42:4, 307-313
CrossRef146
Christopher H. Goss, Nicole Mayer-Hamblett, Richard A. Kronmal, Judy Williams, Bonnie W. Ramsey. (2007) Laboratory parameter profiles among patients with cystic fibrosis. Journal of Cystic Fibrosis 6:2, 117-123
CrossRef147
David A. D'Argenio, Manhong Wu, Lucas R. Hoffman, Hemantha D. Kulasekara, Eric Déziel, Eric E. Smith, Hai Nguyen, Robert K. Ernst, Theodore J. Larson Freeman, David H. Spencer, Mitchell Brittnacher, Hillary S. Hayden, Sara Selgrade, Mikkel Klausen, David R. Goodlett, Jane L. Burns, Bonnie W. Ramsey, Samuel I. Miller. (2007) Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Molecular Microbiology 64:2, 512-533
CrossRef148
Gerd Döring, J. Stuart Elborn, Marie Johannesson, Hugo de Jonge, Matthias Griese, Alan Smyth, Harry Heijerman. (2007) Clinical trials in cystic fibrosis. Journal of Cystic Fibrosis 6:2, 85-99
CrossRef149
Yang Chen, Wei-Guo Huang, Ding-Jun Zha, Jian-Hua Qiu, Jin-Ling Wang, Su-Hua Sha, Jochen Schacht. (2007) Aspirin attenuates gentamicin ototoxicity: From the laboratory to the clinic. Hearing Research 226:1-2, 178-182
CrossRef150
EM Westerman, HGM Heijerman, HW Frijlink. (2007) Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opinion on Drug Delivery 4:2, 91-94
CrossRef151
Jennifer K Hagerman, Stephanie A Knechtel, Michael E Klepser. (2007) Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature. Expert Opinion on Pharmacotherapy 8:4, 467-475
CrossRef152
Ali Hallal, Stephen M. Cohn, Nicholas Namias, Fahim Habib, Gio Baracco, Ronald J. Manning, Bruce Crookes, Carl I. Schulman. (2007) Aerosolized Tobramycin in The Treatment of Ventilator-Associated Pneumonia: A Pilot Study. Surgical Infections 8:1, 73-82
CrossRef153
Rajiv Dhand. (2007) Inhalation therapy in invasive and noninvasive mechanical ventilation. Current Opinion in Critical Care 13:1, 27-38
CrossRef154
Ranjan Suri, Chris Metcalfe, Colin Wallis, Andrew Bush. (2007) Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine 101:2, 254-260
CrossRef155
Alexander Chuchalin, Eszter Csisz??r, K??lm??n Gyurkovics, Maria Trawi??ska Bartnicka, Dorota Sands, Nikolai Kapranov, Guido Varoli, Pier Alessandro Monici Preti, Henryk Mazurek. (2007) A Formulation of Aerosolized Tobramycin (Bramitob??) in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Infection. Pediatric Drugs 9:Supplement 1, 21-31
CrossRef156
Rajiv Dhand, Emmanuelle Mercier. (2007) Effective inhaled drug administration to mechanically ventilated patients. Expert Opinion on Drug Delivery 4:1, 47-61
CrossRef157
Gerard Lenoir, Yuriy Genadievich Antypkin, Angelo Miano, Paolo Moretti, Maurizio Zanda, Guido Varoli, Pier Alessandro Monici Preti, Nikolay Leonidovich Aryayev. (2007) Efficacy, Safety, and Local Pharmacokinetics of Highly Concentrated Nebulized Tobramycin in Patients with Cystic Fibrosis Colonized with Pseudomonas aeruginosa. Pediatric Drugs 9:Supplement 1, 11-20
CrossRef158
Marcus Dahlheim, Hermann Lindemann, Karl P. Paul, Nicolaus Schwerk. 2007. Atemwege. , 871-916.
CrossRef159
James A Driscoll, Steven L Brody, Marin H Kollef. (2007) The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections. Drugs 67:3, 351-368
CrossRef160
Samya Z. Nasr, Diane Gordon, Ermelinda Sakmar, Xin Yu, Emmanuel Christodoulou, Boris P. Eckhardt, Peter J. Strouse. (2006) High resolution computerized tomography of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis patients. Pediatric Pulmonology 41:12, 1129-1137
CrossRef161
H.V. Olesen, J.C. Jensenius, R. Steffensen, S. Thiel, P.O. Schiøtz. (2006) The mannan-binding lectin pathway and lung disease in cystic fibrosis—dysfunction of mannan-binding lectin-associated serine protease 2 (MASP-2) may be a major modifier. Clinical Immunology 121:3, 324-331
CrossRef162
H.A. Tiddens, D.E. Geller, P. Challoner, R.J. Speirs, K.C. Kesser, S.E. Overbeek, D. Humble, S.B. Shrewsbury, T.A. Standaert. (2006) Effect of Dry Powder Inhaler Resistance on the Inspiratory Flow Rates and Volumes of Cystic Fibrosis Patients of Six Years and Older. Journal of Aerosol Medicine 19:4, 456-465
CrossRef163
Steven M Rowe, John P Clancy. (2006) Advances in cystic fibrosis therapies. Current Opinion in Pediatrics 18:6, 604-613
CrossRef164
David Adeboyeku, Sandra Scott, Margaret E. Hodson. (2006) Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. Journal of Cystic Fibrosis 5:4, 261-263
CrossRef165
Alan Smyth. (2006) Update on treatment of pulmonary exacerbations in cystic fibrosis. Current Opinion in Pulmonary Medicine 12:6, 440-444
CrossRef166
Gerd D
ring, Felix Ratjen. 2006. Mucoviscidosis (Cystic Fibrosis), Molecular Cell Biology of. .
CrossRef167
T. O. Hirche, S. Loitsch, C. Smaczny, C. Mallinckrodt, T. O. F. Wagner. (2006) Zystische Fibrose. Der Pneumologe 3:5, 325-339
CrossRef168
Gaudenz M. Hafen, Sarath C. Ranganathan, Colin F. Robertson, Philip J. Robinson. (2006) Clinical scoring systems in cystic fibrosis. Pediatric Pulmonology 41:7, 602-617
CrossRef169
Ronald L. Gibson, George Z. Retsch-Bogart, Christopher Oermann, Carlos Milla, Joseph Pilewski, Cori Daines, Richard Ahrens, Kevin Leon, Morty Cohen, Sharon McNamara, Tracy L. Callahan, Richard Markus, Jane L. Burns. (2006) Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatric Pulmonology 41:7, 656-665
CrossRef170
B. Martha, D. Croisier, D. Durand, D. Hocquet, P. Plesiat, L. Piroth, H. Portier, P. Chavanet. (2006) In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin. Clinical Microbiology and Infection 12:5, 426-432
CrossRef171
Clement L. Ren, Justin L. Brucker, Amy K. Rovitelli, Kimberly A. Bordeaux. (2006) Changes in lung function measured by spirometry and the forced oscillation technique in cystic fibrosis patients undergoing treatment for respiratory tract exacerbation. Pediatric Pulmonology 41:4, 345-349
CrossRef172
Lyndia C. Brumback, Margaret S. Pepe, Todd A. Alonzo. (2006) Using the ROC curve for gauging treatment effect in clinical trials. Statistics in Medicine 25:4, 575-590
CrossRef173
Elkins, Mark R., Robinson, Michael, Rose, Barbara R., Harbour, Colin, Moriarty, Carmel P., Marks, Guy B., Belousova, Elena G., Xuan, Wei, Bye, Peter T.P., . (2006) A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis. New England Journal of Medicine 354:3, 229-240
Full Text174
Ratjen, Felix, . (2006) Restoring Airway Surface Liquid in Cystic Fibrosis. New England Journal of Medicine 354:3, 291-293
Full Text175
Lynne Maxwell, Salvatore R. Goodwin, Thomas J. Mancuso, Victor C. Baum, Aaron L. Zuckerberg, Philip G. Morgan, Etsuro K. Motoyama, Peter J. Davis. 2006. Systemic Disorders in Infants and Children. , 1032-1109.
CrossRef176
Tracy Ann Briggs, Mandy Bryant, Rosalind L. Smyth. (2006) Controlled clinical trials in cystic fibrosis — are we doing better?. Journal of Cystic Fibrosis 5:1, 3-8
CrossRef177
Jennifer K Hagerman, Kim E Hancock, Michael E Klepser. (2006) Aerosolised antibiotics: a critical appraisal of their use. Expert Opinion on Drug Delivery 3:1, 71-86
CrossRef178
2006. Tobramycin. , 3437-3441.
CrossRef179
Felix Ratjen. (2006) Diagnosing and managing infection in CF. Paediatric Respiratory Reviews 7, S151-S153
CrossRef180
Steven P Conway, Daniel G Peckham, Miles Denton, Keith, G Brownlee. (2005) Optimizing treatment policies and improving care: impact on outcome in patients with cystic fibrosis. Expert Review of Pharmacoeconomics & Outcomes Research 5:6, 791-806
CrossRef181
R. Canton, N. Cobos, J. de Gracia, F. Baquero, J. Honorato, S. Gartner, A. Alvarez, A. Salcedo, A. Oliver, E. Garcia-Quetglas, . (2005) Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clinical Microbiology and Infection 11:9, 690-703
CrossRef182
Samuel M. Moskowitz, Ronald L. Gibson, Eric L. Effmann. (2005) Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. Pediatric Radiology 35:8, 739-757
CrossRef183
C.M. Luna, A. Monteverde, A. Rodríguez, C. Apezteguia, G. Zabert, S. Ilutovich, G. Menga, W. Vasen, A.R. Díez, J. Mera. (2005) Neumonía intrahospitalaria: guía clínica aplicable a Latinoamérica preparada en común por diferentes especialistas. Archivos de Bronconeumología 41:8, 439-456
CrossRef184
Vivek N. Ahya, Alden M. Doyle, James D. Mendez, David A. Lipson, Jason D. Christie, Emily A. Blumberg, Alberto Pochettino, Linda Nelson, Roy D. Bloom, Robert M. Kotloff. (2005) Renal and Vestibular Toxicity Due to Inhaled Tobramycin in a Lung Transplant Recipient. The Journal of Heart and Lung Transplantation 24:7, 932-935
CrossRef185
Carla Colombo, Diana Costantini, Alessia Rocchi, Lisa Cariani, Maria Laura Garlaschi, Silvia Tirelli, Giliola Calori, Elena Copreni, Massimo Conese. (2005) Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatric Pulmonology 40:1, 15-21
CrossRef186
Donald R. VanDevanter, Jill M. Van Dalfsen. (2005) How much doPseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?. Pediatric Pulmonology 39:6, 504-506
CrossRef187
Johan W. Mouton, Nico Jacobs, Harm Tiddens, Alphonsus M. Horrevorts. (2005) Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagnostic Microbiology and Infectious Disease 52:2, 123-127
CrossRef188
Jacob Twiss, Cass Byrnes, Roger Johnson, David Holland. (2005) Nebulised gentamicin—suitable for childhood bronchiectasis. International Journal of Pharmaceutics 295:1-2, 113-119
CrossRef189
Stefanie Redmann, Claire Wainwright, Sonya Stacey, Anita Champion, Penny Mitchell, Joyce Cheney, Bruce Charles. (2005) Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI??). Therapeutic Drug Monitoring 27:2, 205-207
CrossRef190
Nelson L Turcios. (2005) Cystic Fibrosis. Journal of Clinical Gastroenterology 39:4, 307-317
CrossRef191
R. Cantón, N. Cobos, J. de Gracia, F. Baquero, J. Honorato, S. Gartner, A. Álvarez, A. Salcedo, A. Oliver, E. García-Quetglas. (2005) Tratamiento antimicrobiano frente a la colonización pulmonar por Pseudomonas aeruginosa en el paciente con fibrosis quística. Archivos de Bronconeumología 41, 1-25
CrossRef192
Akihiko OHWADA, Yuichiro KAJIYAMA, Naoko HIRASHIMA, Atsuko MIYAJI, Masaru SUZUKI. (2004) Inhalation of tobramycin in a patient with aspiration pneumonia as a result of medullary stroke. Respirology 9:4, 564-567
CrossRef193
Lisa Saiman. (2004) The use of macrolide antibiotics in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine 10:6, 515-523
CrossRef194
Timothy D. Murphy, Ran D. Anbar, Lucille A. Lester, Samya Z. Nasr, Bruce Nickerson, Donald R. VanDevanter, Andrew A. Colin. (2004) Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatric Pulmonology 38:4, 314-320
CrossRef195
Randall S. Edson, Robert H. Brey, Thomas J. Mcdonald, Christine L. Terrell, James T. Mccarthy, Janet M. Thibert. (2004) Vestibular Toxicity Due to Inhaled Tobramycin in a Patient With Renal Insufficiency. Mayo Clinic Proceedings 79:9, 1185-1191
CrossRef196
R. S. Edson, R. H. Brey, T. J. McDonald, C. L. Terrell, J. T. McCarthy, J. M. Thibert. (2004) Vestibular Toxicity Due to Inhaled Tobramycin in a Patient With Renal Insufficiency. Mayo Clinic Proceedings 79:9, 1185-1191
CrossRef197
Elizabeth Anne Edwards, Jacob Twiss, Catherine Ann Byrnes. (2004) Treatment of paediatric non-cystic fibrosis bronchiectasis. Expert Opinion on Pharmacotherapy 5:7, 1471-1484
CrossRef198
Dubhfeasa M. Slattery, David Zurakowski, Andrew A. Colin, Robert H. Cleveland. (2004) CF: An X-ray database to assess effect of aerosolized tobramycin. Pediatric Pulmonology 38:1, 23-30
CrossRef199
Gerd Döring, Niels Hoiby. (2004) Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. Journal of Cystic Fibrosis 3:2, 67-91
CrossRef200
Harvey R. Rabin, Steven M. Butler, Mary Ellen B. Wohl, David E. Geller, Andrew A. Colin, Daniel V. Schidlow, Charles A. Johnson, Michael W. Konstan, Warren E. Regelmann, . (2004) Pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology 37:5, 400-406
CrossRef201
Helle Krogh Johansen, Lena N
CrossRef202
Michael E Klepser. (2004) Role of nebulized antibiotics for the treatment of respiratory infections. Current Opinion in Infectious Diseases 17:2, 109-112
CrossRef203
Eliza M. Parker, Brian P. O'Sullivan, Julie C. Shea, Meredith M. Regan, Steven D. Freedman. (2004) Survey of breast-feeding practices and outcomes in the cystic fibrosis population. Pediatric Pulmonology 37:4, 362-367
CrossRef204
Amanda L. Brennan, Duncan M. Geddes. (2004) Bringing new treatments to the bedside in cystic fibrosis. Pediatric Pulmonology 37:2, 87-98
CrossRef205
Sarah Elkin, Duncan Geddes. (2003) Pseudomonal infection in cystic fibrosis: the battle continues. Expert Review of Anti-infective Therapy 1:4, 609-618
CrossRef206
C. J. Dobbin, P. T. P. Bye. (2003) Adults with cystic fibrosis: meeting the challenge!. Internal Medicine Journal 33:12, 593-597
CrossRef207
Margaret Rosenfeld, Bonnie W. Ramsey, Ronald L. Gibson. (2003) Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Current Opinion in Pulmonary Medicine 9:6, 492-497
CrossRef208
Bruce C. Marshall. (2003) Cystic fibrosis. Current Opinion in Pulmonary Medicine 9:6, 484-485
CrossRef209
Robert N. Chernish, Shawn D. Aaron. (2003) Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine 9:6, 509-515
CrossRef210
M Denton, A Rajgopal, L Mooney, A Qureshi, K.G Kerr, V Keer, K Pollard, D.G Peckham, S.P Conway. (2003) Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. Journal of Hospital Infection 55:3, 180-183
CrossRef211
Richard Iles, Julia Legh-Smith, Michael Drummond, Andrew Prevost, Sarah Vowler. (2003) Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. Journal of Cystic Fibrosis 2:3, 120-128
CrossRef212
Gerard Ryan, Somnath Mukhopadhyay, Meenu Singh, Gerard Ryan. 2003. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. .
CrossRef213
J.E. Moore, J. Xu, B.C. Millar, J. Courtney, J.S. Elborn. (2003) Development of a Gram-negative selective agar (GNSA) for the detection of Gram-negative microflora in sputa in patients with cystic fibrosis. Journal of Applied Microbiology 95:1, 160-166
CrossRef214
Douglas J. Conrad. (2003) The Clinical Use of Aerosolized Antibiotics. Clinical Pulmonary Medicine 10:4, 201-207
CrossRef215
D. Grimbert, L. Vecellio, P. Delépine, S. Attucci, E. Boissinot, A. Poncin, F. Gauthier, C. Valat, F. Saudubray, P. Antonioz, P. Diot. (2003) Characteristics of EPI-hNE4 Aerosol: A New Elastase Inhibitor for Treatment of Cystic Fibrosis. Journal of Aerosol Medicine 16:2, 121-129
CrossRef216
David Geller, John Thipphawong, Babatunde Otulana, Daniel Caplan, Dawn Ericson, Laura Milgram, Jerry Okikawa, Joanne Quan, C. Michael Bowman. (2003) Bolus Inhalation of rhDNase with the AERx System in Subjects with Cystic Fibrosis. Journal of Aerosol Medicine 16:2, 175-182
CrossRef217
Larry G. Johnson, Miriam K. Vanhook, Carolyn B. Coyne, Najwa Haykal-Coates, Stephen H. Gavett. (2003) Safety and Efficiency of Modulating Paracellular Permeability to Enhance Airway Epithelial Gene Transfer In Vivo. Human Gene Therapy 14:8, 729-747
CrossRef218
F. B. Spencker, L. Staber, T. Lietz, R. Schille, A. C. Rodloff. (2003) Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times. Clinical Microbiology and Infection 9:5, 370-379
CrossRef219
Deborah A. Kahler, Kenneth O. Schowengerdt, F. Jay Fricker, Melissa Mansfield, Gary A. Visner, Albert Faro. (2003) Toxic Serum Trough Concentrations After Administration of Nebulized Tobramycin. Pharmacotherapy 23:4, 543-545
CrossRef220
Keith J. Wahl, Alan Otsuji. (2003) New medical management techniques for acute exacerbations of chronic rhinosinusitis. Current Opinion in Otolaryngology & Head and Neck Surgery 11:1, 27-32
CrossRef221
Felix Ratjen, Gerd Döring. (2003) Cystic fibrosis. The Lancet 361:9358, 681-689
CrossRef222
Kenneth J. Rothman, Charles E. Wentworth. (2003) Mortality of Cystic Fibrosis Patients Treated with Tobramycin Solution for Inhalation. Epidemiology 14:1, 55-59
CrossRef223
Susan M Cheer, John Waugh, Stuart Noble. (2003) Inhaled Tobramycin (TOBI??). Drugs 63:22, 2501-2520
CrossRef224
Christian Krauth, Noushin Jalilvand, Tobias Welte, Reinhard Busse. (2003) Cystic Fibrosis. PharmacoEconomics 21:14, 1001-1024
CrossRef225
Niels Høiby. (2002) Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. Journal of Cystic Fibrosis 1:4, 249-254
CrossRef226
J.R.W. Govan. (2002) Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. Journal of Cystic Fibrosis 1, 203-208
CrossRef227
Don Kellerman, Richard Evans, Dave Mathews, Christy Shaffer. (2002) Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease. Advanced Drug Delivery Reviews 54:11, 1463-1474
CrossRef228
A.L Smith. (2002) Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?. Journal of Cystic Fibrosis 1, 189-193
CrossRef229
Jack A Kastelik, Graham A Wright, Imran Aziz, Mal Davies, Gerard R Avery, Alex J Paddon, Sydney Howey, Alyn H Morice. (2002) A Widely Available Method for the Assessment of Aerosol Delivery in Cystic Fibrosis. Pulmonary Pharmacology & Therapeutics 15:6, 513-519
CrossRef230
M.E Hodson, C.G Gallagher. (2002) New clinical evidence from the European tobramycin trial in cystic fibrosis. Journal of Cystic Fibrosis 1, 199-202
CrossRef231
OANA CIOFU, NIELS BAGGE, NIELS HOIBY. (2002) Antibodies against beta-lactamase can improve ceftazidime treatment of lung infection with beta-lactam-resistant Pseudomonas aeruginosa in a rat model of chronic lung infection. APMIS 110:12, 881-891
CrossRef232
Ingrid M. Hoffmann, Bruce K. Rubin, Samy S. Iskandar, Michael S. Schechter, Shashi K. Nagaraj, Martin M. Bitzan. (2002) Acute renal failure in cystic fibrosis: Association with inhaled tobramycin therapy. Pediatric Pulmonology 34:5, 375-377
CrossRef233
N. David Yanez Iii, Richard A. Kronmal, Jennifer C. Nelson, Todd A. Alonzo. (2002) Analysing change in clinical trials using quasi-likelihoods. Journal of Applied Statistics 29:8, 1135-1145
CrossRef234
Thao Nguyen, Stan G. Louie, Paul M. Beringer, Mark A. Gill. (2002) Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Current Opinion in Pulmonary Medicine 8:6, 521-528
CrossRef235
Theodore G. Liou, Barbara C. Cahill, Frederick R. Adler, Bruce C. Marshall. (2002) Selection of patients with cystic fibrosis for lung transplantation. Current Opinion in Pulmonary Medicine 8:6, 535-541
CrossRef236
Steven P. Conway. (2002) Evidence-based medicine in cystic fibrosis: How should practice change?. Pediatric Pulmonology 34:3, 242-247
CrossRef237
Charles W. Callahan, Gregory J. Redding. (2002) Bronchiectasis in children: Orphan disease or persistent problem?. Pediatric Pulmonology 33:6, 492-496
CrossRef238
Christopher J. Crnich, Dennis G. Maki. (2002) The Promise of Novel Technology for the Prevention of Intravascular Device–Related Bloodstream Infection. I. Pathogenesis and Short‐Term Devices. Clinical Infectious Diseases 34:9, 1232-1242
CrossRef239
Alexandra L. Quittner, Anne Buu. (2002) Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis andPseudomonas aeruginosa infection. Pediatric Pulmonology 33:4, 269-276
CrossRef240
Amanda L. Brennan, Duncan M. Geddes. (2002) Cystic fibrosis. Current Opinion in Infectious Diseases 15:2, 175-182
CrossRef241
Michael G. Spigarelli, Martin E. Hurwitz, Samya Z. Nasr. (2002) Hypersensitivity to inhaled TOBI
CrossRef242
Robert J. Kuhn. (2002) Pharmaceutical Considerations in Aerosol Drug Delivery. Pharmacotherapy 22:3 Part 2, 80S-85S
CrossRef243
Martin J. Ledson, Malcolm J. Gallagher, Maxine Robinson, Carolyn Cowperthwaite, Trevor Williets, Charles A. Hart, Martin J. Walshaw. (2002) A Randomized Double-Blinded Placebo-Controlled Crossover Trial of Nebulized Taurolidine in Adult Cystic Fibrosis Patients Infected with Burkholderia cepacia. Journal of Aerosol Medicine 15:1, 51-57
CrossRef244
Patrick Flume, Michael E. Klepser. (2002) The Rationale for Aerosolized Antibiotics. Pharmacotherapy 22:3 Part 2, 71S-79S
CrossRef245
Bernd Heinzl, Ernst Eber, B
CrossRef246
Isabelle Sermetgaudelus, Yann Lecocguic, Agnes Ferroni, Marlene Clairicia, Joel Barthe, Janpierre Delaunay, Valentine Brousse, Gerard Lenoir. (2002) Nebulized Antibiotics in Cystic Fibrosis. Pediatric Drugs 4:7, 455-467
CrossRef247
A. Bush. (2001) Six of the best: cystic fibrosis. Paediatric Respiratory Reviews 2:4, 287-293
CrossRef248
Paul Beringer. (2001) The clinical use of colistin in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine 7:6, 434-440
CrossRef249
Bertrand J. Shapiro. (2001) Cystic fibrosis. Current Opinion in Pulmonary Medicine 7:6, 419-420
CrossRef250
Ellen H. Elpern, Jeannine Cheatham. (2001) Inpatient Care of the Adult With an Exacerbation of Cystic Fibrosis. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 12:2, 293-304
CrossRef251
James M Littlewood, John RW Govan. (2001) Elusiveness of cysticfibrosis treatment. The Lancet 357:9256, 633-634
CrossRef252
Niels Høiby, Helle Krogh Johansen, Claus Moser, Zhijun Song, Oana Ciofu, Arsalan Kharazmi. (2001) Pseudomonas aeruginosa and the in vitroand in vivo biofilm mode of growth. Microbes and Infection 3:1, 23-35
CrossRef253
Jasjit Singh, Bill Burr, Del Stringham, Antonio Arrieta. (2001) Commonly Used Antibacterial and Antifungal Agents for Hospitalised Paediatric Patients. Paediatric Drugs 3:10, 733-761
CrossRef254
L. V. Sacks, S. Pendle, D. Orlovic, M. Andre, M. Popara, G. Moore, L. Thonell, S. Hurwitz. (2001) Adjunctive Salvage Therapy with Inhaled Aminoglycosides for Patients with Persistent Smear-Positive Pulmonary Tuberculosis. Clinical Infectious Diseases 32:1, 44-49
CrossRef255
L Mooney, K.G Kerr, M Denton. (2001) Survival of Stenotrophomonas maltophilia following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients. International Journal of Antimicrobial Agents 17:1, 63-66
CrossRef256
Mark R. Tonelli, Moira L. Aitken. (2001) New and Emerging Therapies for Pulmonary Complications of Cystic Fibrosis. Drugs 61:10, 1379-1385
CrossRef257
Todd F. Hatchette, Rekha Gupta, Thomas J. Marrie. (2000) Pseudomonas aeruginosa Community‐Acquired Pneumonia in Previously Healthy Adults: Case Report and Review of the Literature. Clinical Infectious Diseases 31:6, 1349-1356
CrossRef258
C. Gysin, G.A. Alothman, B.C. Papsin. (2000) Sinonasal disease in cystic fibrosis: Clinical characteristics, diagnosis, and management. Pediatric Pulmonology 30:6, 481-489
CrossRef259
Dev Banerjee, David Stableforth. (2000) The Treatment of Respiratory Pseudomonas Infection in Cystic Fibrosis. Drugs 60:5, 1053-1064
CrossRef260
Niels H??iby. (2000) Prospects for the Prevention and Control of Pseudomonal Infection in Children with Cystic Fibrosis. Paediatric Drugs 2:6, 451-463
CrossRef261
Petra Borsje, Johan C. de Jongste, Johan W. Mouton, Harm A.W.M. Tiddens. (2000) Aerosol therapy in cystic fibrosis: A survey of 54 CF centers. Pediatric Pulmonology 30:5, 368-376
CrossRef262
Bruce C Marshall, Theodore G Liou. (2000) Elusiveness of ideal approach to Pseudomona aeruginosa infection complicating cystic fibrosis. The Lancet 356:9230, 613-614
CrossRef263
Robert E.W. Hancock, David P. Speert. (2000) Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resistance Updates 3:4, 247-255
CrossRef264
J.M. LITTLEWOOD, C. KOCH, P.A. LAMBERT, N. HØIBY, J.S. ELBORN, S.P. CONWAY, R. DINWIDDIE, F. DUNCAN-SKINGLE. (2000) A ten year review of Colomycin. Respiratory Medicine 94:7, 632-640
CrossRef265
Igor Gonda. (2000) The ascent of pulmonary drug delivery. Journal of Pharmaceutical Sciences 89:7, 940-945
CrossRef266
T. A. Standaert, D. VanDevanter, B. W. Ramsey, M. Vasiljev-K, P. Nardella, D. Gmur, C. Bredl, A. Murphy, A. B. Montgomery. (2000) The Choice of Compressor Effects the Aerosol Parameters and the Delivery of Tobramycin from a Single Model Nebulizer. Journal of Aerosol Medicine 13:2, 147-153
CrossRef267
Yau Hong Goh, Richard L. Goode. (2000) State of the Art Review: Current Status of Topical Nasal Antimicrobial Agents. The Laryngoscope 110:6, 875-880
CrossRef268
J Mouton. (2000) Antibiotic treatment in cystic fibrosis Part 2: Dose optimization. Antimicrobics and Infectious Diseases Newsletter 18:5, 33-37
CrossRef269
Maya Ramagopal, Larry C. Lands. (2000) Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis. Pediatric Pulmonology 29:5, 366-370
CrossRef270
&NA;. (2000) Inhaled tobramycin: take a deep breath in CF. Drugs & Therapy Perspectives 15:3, 1-5
CrossRef271
G. Christopher Wood, Bradley A. Boucher. (2000) Aerosolized Antimicrobial Therapy in Acutely Ill Patients. Pharmacotherapy 20:2, 166-181
CrossRef272
T. TODISCO, A. ESLAMI, S. BAGLIONI, T. SPOSINI, C. TASCINI, E. SOMMER, M. KNOCH. (2000) Basis for Nebulized Antibiotics: Droplet Characterization and In Vitro Antimicrobial Activity Versus Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Journal of Aerosol Medicine 13:1, 11-16
CrossRef273
Jacques LeLorier, Sylvie Perreault, Howard Birnbaum, Paul Greenberg, Odile Sheehy. (2000) Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis. Clinical Therapeutics 22:1, 140-151
CrossRef274
Okan Elidemir, Stephanie R. Maciejewski, Christopher M. Oermann. (2000) Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin. Pediatric Pulmonology 29:1, 43-45
CrossRef275
Paul P. H. Le Brun, Alexander A. T. M. M. Vinks, Daan J. Touw, Nicole Hekelaar, Gregor P. M. Mannes, Roland W. Brimicombe, Erik H. W. Frijlink, Harry G. M. Heijerman. (1999) Can Tobramycin Inhalation Be Improved With a Jet Nebulizer?. Therapeutic Drug Monitoring 21:6, 618
CrossRef276
J. Bargon, N. Dauletbaev, B. Köhler, M. Wolf, H.-G. Posselt, T.O.F. Wagner. (1999) Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respiratory Medicine 93:11, 835-838
CrossRef277
Paul M. Beringer. (1999) New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine 5:6, 371
CrossRef278
Pallav L Shah. (1999) Update on clinical trials in the treatment of pulmonary disease in patients with cystic fibrosis. Expert Opinion on Investigational Drugs 8:11, 1917-1927
CrossRef279
Michael W. Konstan, Steven M. Butler, Daniel V. Schidlow, Wayne J. Morgan, Joanne R. Julius, . (1999) Patterns of medical practice in cystic fibrosis: Part II. Use of therapies. Pediatric Pulmonology 28:4, 248-254
CrossRef280
Marc Foca, Sujatha Rajan, Lisa Saiman. (1999) Rational treatment of pulmonary infections in patients with cystic fibrosis. Current Opinion in Infectious Diseases 12:3, 257-263
CrossRef281
Randall S. Edson, Christine L. Terrell. (1999) The Aminoglycosides. Mayo Clinic Proceedings 74:5, 519-528
CrossRef282
Randall S. Edson, Christine L. Terrell. (1999) The Aminoglycosides. Mayo Clinic Proceedings 74:5, 519-528
CrossRef283
R. L. HENRY. (1999) Antipseudomonal antibiotics and cystic fibrosis. Australian and New Zealand Journal of Medicine 29:1, 5-8
CrossRef
